Gene Solutions Indonesia Continues Roadshow with PDPI West Java to Introduce Genomic Innovation for Lung Cancer Treatment

  • News

On August 25, 2024, in an ongoing effort to advance the field of cancer treatment, Gene Solutions Indonesia teamed up with the Indonesian Society of Respirology (ISR/PDPI) West Java branch in Bandung, Indonesia. The collaboration aimed to introduce and explore the application of groundbreaking genomic innovations in lung cancer treatment and early multi-cancer detection.

Welcome message from the Chairperson of PDPI West Java.
Welcome message from the Chairperson of PDPI West Java.
Dr. Widhy Y. Nalapraya, M. Kes, Sp. P(K)Onk presenting
Dr. Widhy Y. Nalapraya, M. Kes, Sp. P(K)Onk presenting
Dr. Sita L. Andarini, Ph.D., Sp. P(K) presenting
Dr. Sita L. Andarini, Ph.D., Sp. P(K) presenting

The event, moderated by the esteemed Dr. Sri W. Pamungkasningsih, Sp. P(K)Onk, featured a compelling keynote presentation by Dr. Sita L. Andarini, Ph.D., Sp. P(K), highlighting the Implementation of advanced technology in lung cancer from molecular diagnosis and monitoring. Furthermore, Dr. Widhy Y. Nalapraya, M. Kes, Sp. P(K)Onk, presented a compelling case study on the challenges in lung cancer monitoring and potential treatment solutions.

Gene Solutions Indonesia Team presenting K-TRACK (Hera) and SPOT-MAS (Ari) Gene Solutions Indonesia Team presenting K-TRACK (Hera) and SPOT-MAS (Ari)

The discussion was met with great enthusiasm from the audience, who actively participated in conversations about how genomic technology can positively impact preventive measures and aid in cancer treatment monitoring. Gene Solutions Indonesia highlighted the advancements, including the K-track for cancer monitoring and the multi-cancer early detection test “SPOT-MAS,” illustrating their potential impact to enhance patient outcomes, especially in lung cancer. The event provided valuable opportunities to engage with industry professionals and further the goal of advancing genomic solutions for improved healthcare.

About Gene Solutions Indonesia:

Established in 2022, PT Gene Solutions Indonesia has been diligently advancing genetic testing and providing essential support to healthcare practitioners. We recognize the significance of Next-Generation Sequencing (NGS) in prenatal care and molecular diagnostics. Through our valued partnership with KALGen INNOLAB, we strive to make Non-Invasive Prenatal Testing (NIPT) and oncology diagnostics accessible to the Indonesian population.

Follow Gene Solutions Indonesia on Instagram to get latest update. https://www.instagram.com/genesolutions.id/

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More